• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Retrospective study of the efficacy and safety of treatment with PDD vs PAD in de novo patients with multiple myiloma].[初诊多发性骨髓瘤患者中硼替佐米与帕比司他治疗疗效及安全性的回顾性研究] 。 注：原文中“myiloma”拼写有误，正确的是“myeloma” 。
Zhonghua Xue Ye Xue Za Zhi. 2015 Apr;36(4):340-3. doi: 10.3760/cma.j.issn.0253-2727.2015.04.018.
2
[A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].一项比较硼替佐米联合地塞米松与硼替佐米、表柔比星和地塞米松治疗多发性骨髓瘤患者疗效及安全性的队列研究
Zhonghua Nei Ke Za Zhi. 2016 Sep 1;55(9):689-94. doi: 10.3760/cma.j.issn.0578-1426.2016.09.007.
3
[PAD regimen for relapsed or refractory patients with multiple myeloma].复发或难治性多发性骨髓瘤患者的PAD方案
Zhonghua Xue Ye Xue Za Zhi. 2009 Apr;30(4):260-3.
4
[Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novo patients with multiple myeloma].皮下注射硼替佐米治疗初发多发性骨髓瘤患者的疗效与安全性研究
Zhonghua Xue Ye Xue Za Zhi. 2013 Oct;34(10):868-72. doi: 10.3760/cma.j.issn.0253-2727.2013.10.009.
5
Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma.
Expert Rev Anticancer Ther. 2009 Jul;9(7):885-90. doi: 10.1586/era.09.52.
6
[Efficacy comparison between standard and reduced doses of bortezomib combined with adriamycin and dexamethasone in the treatment of patients with multiple myeloma].硼替佐米标准剂量与减量剂量联合阿霉素和地塞米松治疗多发性骨髓瘤患者的疗效比较
Zhonghua Xue Ye Xue Za Zhi. 2013 Jul;34(7):622-5. doi: 10.3760/cma.j.issn.0253-2727.2013.07.014.
7
[The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma].[PAD和VAD方案用于初治多发性骨髓瘤的疗效与安全性]
Zhonghua Nei Ke Za Zhi. 2010 Sep;49(9):762-4.
8
[Adverse effects of PAD and VAD regimens in multiple myeloma patients].[多发性骨髓瘤患者中PAD和VAD方案的不良反应]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Aug;18(4):1027-30.
9
Immortal time bias in retrospective analysis: comment on 'Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma'.
Blood Cancer J. 2015 Feb 27;5(2):e283. doi: 10.1038/bcj.2015.4.
10
[Tandem double autologous peripheral blood stem cell transplants for de novo multiple myeloma].[串联双次自体外周血干细胞移植治疗初发性多发性骨髓瘤]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):131-4.

本文引用的文献

1
Multiple myeloma, version 1.2013.多发性骨髓瘤，第 1.2013 版。
J Natl Compr Canc Netw. 2013 Jan 1;11(1):11-7. doi: 10.6004/jnccn.2013.0004.
2
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.硼替佐米诱导和维持治疗新诊断多发性骨髓瘤患者：随机 III 期 HOVON-65/GMMG-HD4 试验结果。
J Clin Oncol. 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820. Epub 2012 Jul 16.
3
Multiple myeloma.多发性骨髓瘤
N Engl J Med. 2011 Mar 17;364(11):1046-60. doi: 10.1056/NEJMra1011442.
4
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.硼替佐米联合地塞米松优于长春新碱联合多柔比星联合地塞米松作为新诊断多发性骨髓瘤患者自体造血干细胞移植前的诱导治疗：IFM 2005-01 期 III 期试验结果。
J Clin Oncol. 2010 Oct 20;28(30):4621-9. doi: 10.1200/JCO.2009.27.9158. Epub 2010 Sep 7.
5
Improved survival in multiple myeloma and the impact of novel therapies.多发性骨髓瘤患者生存率的提高及新型疗法的影响
Blood. 2008 Mar 1;111(5):2516-20. doi: 10.1182/blood-2007-10-116129. Epub 2007 Nov 1.
6
Recent major improvement in long-term survival of younger patients with multiple myeloma.年轻多发性骨髓瘤患者长期生存率近期有显著改善。
Blood. 2008 Mar 1;111(5):2521-6. doi: 10.1182/blood-2007-08-104984. Epub 2007 Sep 27.
7
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.复发多发性骨髓瘤3期试验的长期随访：APEX试验的最终事件发生时间结果
Blood. 2007 Nov 15;110(10):3557-60. doi: 10.1182/blood-2006-08-036947. Epub 2007 Aug 9.
8
Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.聚乙二醇化脂质体阿霉素、长春新碱和地塞米松与阿霉素、长春新碱和地塞米松相比，可显著降低新诊断的多发性骨髓瘤患者的毒性：一项III期多中心随机试验。
Cancer. 2006 Feb 15;106(4):848-58. doi: 10.1002/cncr.21662.
9
Role of liposomal anthracyclines in the treatment of multiple myeloma.脂质体蒽环类药物在多发性骨髓瘤治疗中的作用。
Semin Oncol. 2004 Dec;31(6 Suppl 13):147-60. doi: 10.1053/j.seminoncol.2004.08.005.
10
Multiple myeloma.多发性骨髓瘤
N Engl J Med. 2004 Oct 28;351(18):1860-73. doi: 10.1056/NEJMra041875.

[Retrospective study of the efficacy and safety of treatment with PDD vs PAD in de novo patients with multiple myiloma].

作者信息

Ma Ling, Fu Chengcheng, Liu Hui, Jin Song, Gu Bin, Yan Shuang, Wang Panfeng, Xu Yun, Xue Shengli, Li Weiyang, Sun Aining, Wu Depei

机构信息

The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2015 Apr;36(4):340-3. doi: 10.3760/cma.j.issn.0253-2727.2015.04.018.

DOI:10.3760/cma.j.issn.0253-2727.2015.04.018
PMID:25916300
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7342610/
Abstract
摘要